Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-704-4040
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$41.37 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Harrow Health (NASDAQ:HROW) Frequently Asked Questions
What is Harrow Health's stock symbol?
Harrow Health trades on the NASDAQ under the ticker symbol "HROW."
How were Harrow Health's earnings last quarter?
Harrow Health (NASDAQ:HROW) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. The company had revenue of $13.52 million for the quarter, compared to analysts' expectations of $12.55 million. Harrow Health had a net margin of 51.32% and a return on equity of 50.32%. View Harrow Health's Earnings History.
When is Harrow Health's next earnings date?
What price target have analysts set for HROW?
1 brokers have issued 12-month target prices for Harrow Health's stock. Their predictions range from $15.00 to $15.00. On average, they expect Harrow Health's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 186.8% from the stock's current price. View Analyst Price Targets for Harrow Health.
What is the consensus analysts' recommendation for Harrow Health?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harrow Health.
Has Harrow Health been receiving favorable news coverage?
News coverage about HROW stock has been trending negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Harrow Health earned a news impact score of -2.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Harrow Health.
Are investors shorting Harrow Health?
Harrow Health saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,161,200 shares, an increase of 15.6% from the July 31st total of 1,004,800 shares. Based on an average daily volume of 334,700 shares, the short-interest ratio is currently 3.5 days. Approximately 5.0% of the company's shares are sold short. View Harrow Health's Current Options Chain.
Who are some of Harrow Health's key competitors?
Some companies that are related to Harrow Health include Akero Therapeutics (AKRO), Flexion Therapeutics (FLXN), IGM Biosciences (IGMS), Basilea Pharmaceutica (BPMUF), Achillion Pharmaceuticals (ACHN), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Aptorum Group (APM), Akorn (AKRX), Retrophin (RTRX), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Sinovac Biotech (SVA), ChemoCentryx (CCXI) and Lannett (LCI).
What other stocks do shareholders of Harrow Health own?
Who are Harrow Health's key executives?
Harrow Health's management team includes the folowing people:
- Mr. Mark L. Baum, Founder, CEO & Director (Age 46)
- Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 37)
- Mr. John P. Saharek, Chief Commercial Officer (Age 59)
- Mr. David Moufarrège, VP of Technology
- Mr. Pramod Sharma Ph.D., VP of Quality
Who are Harrow Health's major shareholders?
Which major investors are selling Harrow Health stock?
How do I buy shares of Harrow Health?
Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Harrow Health's stock price today?
One share of HROW stock can currently be purchased for approximately $5.23.
How big of a company is Harrow Health?
Harrow Health has a market capitalization of $131.64 million and generates $41.37 million in revenue each year. The company earns $14.63 million in net income (profit) each year or $0.61 on an earnings per share basis. View Additional Information About Harrow Health.
What is Harrow Health's official website?
How can I contact Harrow Health?
Harrow Health's mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The company can be reached via phone at 858-704-4040 or via email at [email protected]
MarketBeat Community Rating for Harrow Health (NASDAQ HROW)
MarketBeat's community ratings are surveys of what our community members think about Harrow Health and other stocks. Vote "Outperform" if you believe HROW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HROW will underperform the S&P 500 over the long term. You may vote once every thirty days.
